Graeme Duncan, MB ChB FRCPC

Clinical Professor
University of British Columbia (UBC)

Director of Skin Cancer Radiation Oncology
Radiation Oncologist
BC Cancer – Vancouver Centre*
Active Clinical Staff: (Consultant) Vancouver General Hospital (VGH)

Health Authority: Provincial Health Services

Address: BCCA-VCC
600 West 10th Avenue
Vancouver, BC V5Z 4E6

Phone: 604.877.6000 Fax: 604.877.0505

Major Clinical Focus – Palliative care, Quality of Life, Holistic care in oncology

• Bachelor of Medicine, University of Edinburgh, United Kingdom, 1981
• Bachelor of Science (Medical Sciences), University of Edinburgh, United Kingdom, 1978

• Fellow of The Royal of Physicians of Canada (Radiation Oncology), University of Ottawa, Ottawa, Ontario, Canada, 1986-1987
• Fellow of The Royal College of Physicians of Canada, Royal College of Physicians & Surgeons of Canada, Canada, 1987
• Membership of the Royal Colleges of Physicians of the United Kingdom (Internal Medicine), University of Glasgow, Glasgow, United Kingdom, 1981-1984

I have expertise in GU and skin oncology as well as patient communication, supportive (and spiritual) care / symptom control. I have experience of quantitative and qualitative methodologies such as quality of life research – formulation, administration and statistical analysis. I represented Radiation Oncology on the Ethics Committee, then the Priorities and Evaluation Committee, reporting to the BC Cancer Agency Executive on ranking evidence based new therapies. In the last several years I have devoted considerable administrative and bedside teaching energy for UBC medical undergraduates. I continue to work in a busy oncology practice. I have continued my contribution to research – in recent years mainly focusing on quality of life outcomes, in particular the lead QOL investigator on major prostate cancer trials.


Maher EJ, Coia L, Duncan G, Lawton PA. ‘Treatment Strategies in Advanced and Metastatic Cancer: Differences in Attitudes between the USA, Canada and Europe’. Int J Radiat Oncol Biol Phys 23(1): 239-244; 1992

Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, Duncan G, Skingley P, Foster G, Levine M. “A Randomized Trial to Assess the Efficacy of Surgery in Addition to Radiotherapy in Patients with a Single Cerebral Metastasis.” Cancer 78(7), 1470-1476; 1996

Pickles T, Goodman GB, Rheaume DE, Duncan GG, Fryer CJ, Bhimji S, Ludgate C, Syndikus I, Graham P, Dimitrov M, Bowen J. “Pion Radiation for High Grade Astrocytoma: Results of a Randomized Study.” Int J Radiation Biol Phys 37(3), 491-497; 1997

Pickles T, Goodman GB, Fryer CJ, Bowen J, Coldman AJ, Duncan GG, Graham P, McKenzie M, Morris WJ, Rheaume DE, Syndikus I. “Pion conformal radiation of prostate cancer: results of a randomized study.” Int J Rad Oncol Biol Phys 43(2): 47-55, 1999

Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, Pater J, National Cancer Institute of Canada Clinical Trials Group. National Cancer Institute of Canada Clinical Trials Group. “Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.” Head & Neck; 27(5):421-8, 2005

Duncan GG, Corbett T, Lukka, H, Warde, P, Pickles, T. “GU Radiation Oncologists Consensus on bone loss from androgen deprivation.” Can J Urol Feb;13(1):2962-6, 2006

Dennis K, Duncan G. Spiritual care in a multicultural oncology environment. Current Opinion in Supportive & Palliative Care 2012, 6:247–253. [Invited paper]

Crook JM, O’Callaghan CJ, Duncan GG, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. “Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy” N Engl J Med 2012; 367:895-903

Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.
ASCENDE-RT: An analysis of survival endpoints for a randomized trial comparing low-dose-rate brachytherapy boost to dose-escalated external beam boost for high- and intermediate-risk prostate cancer Int J Radiat Oncol Biol Phys. 2017 June 1; 98(2), 275-285.

Rodda S, Morris WJ, Hamm J, Duncan G ASCENDE-RT: An analysis of health related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost to dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
Int J Radiat Oncol Biol Phys. Online 21 Feb 2017.

Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie m, Duncan G et al. ASCENDE-RT: An analysis of treatment related morbidity for a randomized trial comparing Low-Dose-Rate brachytherapy boost with a dose escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017 June 1; 98(2), 286-295.

BC Cancer – Vancouver Centre (VC) is the largest academic cancer centre for BC Cancer, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BC Cancer – Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam and VERO), 1 cobalt, VMAT (first developed in here), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.